S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

AbCellera Biologics Stock Price, News & Analysis (NASDAQ:ABCL)

$4.87
+0.03 (+0.62%)
(As of 12/8/2023 ET)
Compare
Today's Range
$4.70
$4.97
50-Day Range
$3.91
$4.85
52-Week Range
$3.87
$11.38
Volume
1.52 million shs
Average Volume
2.06 million shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.11

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
317.2% Upside
$20.11 Price Target
Short Interest
Bearish
13.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of AbCellera Biologics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

450th out of 960 stocks

Pharmaceutical Preparations Industry

162nd out of 372 stocks


ABCL stock logo

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

ABCL Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Analysts Set AbCellera Biologics Inc. (NASDAQ:ABCL) PT at $21.88
AbCellera Biologics (NASDAQ:ABCL) Shares Down 3.4%
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
AbCellera Biologics Inc Ordinary Shares
AbCellera Reports Q3 2023 Business Results
Small-Cap Biotech Needs Some Emergency Care
AbCellera's Clinical Carousel: High Risk, Higher Stakes
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
630
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.11
High Stock Price Target
$34.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+313.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$158.52 million
Net Margins
-256.27%
Pretax Margin
-311.24%

Debt

Sales & Book Value

Annual Sales
$485.42 million
Cash Flow
$0.68 per share
Book Value
$4.31 per share

Miscellaneous

Free Float
196,010,000
Market Cap
$1.41 billion
Optionable
Not Optionable
Beta
0.28
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 48)
    CEO, President & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A. (Age 49)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 38)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 53)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 53)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Senior Director of Finance & Accounting
  • Dr. Ester Falconer Ph.D. (Age 48)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Manager of Investor Relations
  • Ms. Tiffany Chiu B.Sc.
    Ph.D., Vice President of Communications
  • Graham Craig M.Sc.
    Director of Corporate Development














ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price target for 2024?

11 brokerages have issued 1 year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $34.00. On average, they expect the company's stock price to reach $20.11 in the next year. This suggests a possible upside of 317.2% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2023?

AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 52.4% and is now trading at $4.82.
View the best growth stocks for 2023 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) announced its earnings results on Thursday, November, 2nd. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company earned $6.60 million during the quarter, compared to analysts' expectations of $11.92 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 10.72% and a negative net margin of 256.27%.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.03%), Federated Hermes Inc. (1.12%), Lazard Asset Management LLC (1.08%), American Century Companies Inc. (0.33%), Royal Bank of Canada (0.14%) and Schonfeld Strategic Advisors LLC (0.12%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -